Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from ProKidney ( (PROK) ) is now available.
ProKidney has updated its investor presentation, outlining progress and plans for rilparencel, its autologous kidney cell therapy designed to stabilize kidney function and delay or prevent dialysis in advanced chronic kidney disease patients at highest risk of kidney failure. In 2025, the company aligned with the U.S. Food and Drug Administration on an accelerated approval pathway using eGFR slope as a surrogate endpoint, reported positive Phase 2 data at a major nephrology conference, accelerated enrollment in its pivotal Phase 3 PROACT 1 trial, and expanded its dedicated manufacturing facilities to support both clinical supply and future commercial launch. Looking ahead to 2026, ProKidney aims to complete enrollment for the accelerated approval analysis by mid-year, continue generating and presenting mechanistic data, maintain regulatory dialogue under its RMAT designation in preparation for a potential biologics license application in 2027, and further build out its scalable manufacturing infrastructure, with current cash projected to fund operations into mid-2027, underscoring a period of focused execution that could be pivotal for patients, investors and partners in the kidney disease treatment landscape.
The most recent analyst rating on (PROK) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on ProKidney stock, see the PROK Stock Forecast page.
Spark’s Take on PROK Stock
According to Spark, TipRanks’ AI Analyst, PROK is a Neutral.
The score is held down primarily by weak financial performance: very small revenue relative to large operating losses, substantial ongoing cash burn, and deeply negative equity. Technicals are mildly bearish (below key moving averages with soft momentum), and valuation is unattractive due to losses (negative P/E) with no dividend support.
To see Spark’s full report on PROK stock, click here.
More about ProKidney
ProKidney is a clinical-stage biotechnology company focused on transforming chronic kidney disease care through innovative cell therapies. Its lead product candidate, rilparencel, is a first-in-class, autologous kidney cell therapy for patients with stage 3b/4 chronic kidney disease associated with type 2 diabetes, targeting a U.S. population of more than one million high-risk patients and supported by an expanding in-house manufacturing footprint in Winston-Salem, North Carolina.
Average Trading Volume: 1,398,951
Technical Sentiment Signal: Hold
Current Market Cap: $710M
For detailed information about PROK stock, go to TipRanks’ Stock Analysis page.